Market Overview

Global In-Vitro Diagnostics (IVD) Market Size, Share & Trends 2013-2018 & 2022 - Analysis By Product, Application, Technology, End User And Segment Forecasts -


The "In
Vitro Diagnostics (IVD) Market Size, Share & Trends Analysis Report By
Product, By Application, By Technology (Clinical Chemistry, Molecular
Diagnostics, Coagulation, Microbiology), By End User, And Segment
Forecasts, 2013 - 2022"
report has been added to's

The global in vitro diagnostics (IVD) market size is expected to reach
USD 97.01 billion by 2022, rising at a CAGR of 6.8% during the forecast

Increasing incidence of sexually transmitted and gastrointestinal
diseases coupled with surging demand for large-scale screening,
particularly for cancer, is stimulating the growth of the market. IVD
helps in detecting whether a particular medicine or treatment would work
on a patient.

Constant innovations and advancements play a pivotal role in the
development of the market. IVD is being increasingly used in every stage
of the patient care and nearly each healthcare setting. Though, most of
these tests are remotely performed, making their presence unnoticed.

Various organizations are functioning to monitor the market. For
instance, BIVDA is an association of companies with high involvement and
interest and represents manufacturers and distributors functioning in
the U.K.

Rapidly changing healthcare environment and growing acknowledgment of
diagnostics role in patient care, along with rising awareness regarding
importance of early diagnosis of chronic diseases, are likely to boost
the growth of the IVD market.

Surging demand for point-of-care detection and identification of various
infectious diseases such respiratory tract infections, including
Legionnaires' disease, RSV, influenza, and pneumonia, coupled with
pathogens causing filariasis and malaria, is providing a significant
push to the market.

Key Topics Covered:

Chapter 1. Executive Summary

Chapter 2. IVD Industry Outlook

Chapter 3. IVD Product Outlook

Chapter 4. IVD Regional Outlook

Chapter 5. Competitive Landscape

Chapter 6. Methodology and Scope

Companies Mentioned

  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthcare
  • Johnson and Johnson
  • Bio-Rad Laboratories
  • Beckman Coulter Inc.
  • Becton Dickinson
  • bioMerieux
  • Sysmex
  • Bayer Healthcare
  • Alere Inc.
  • Danaher Corporation
  • Hologic (Gen-Probe)
  • Novartis
  • Cepheid
  • Qiagen
  • Leica Biosystems
  • Dako

For more information about this report visit

View Comments and Join the Discussion!